Healthcare: Is Zolgensma's $2.1 Million Price Tag Ridiculous?

23:14
 
Share
 

Manage episode 234966523 series 2394758
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Here's why paying $2 million for Novartis' revolutionary gene therapy for SMA may not be as crazy as it sounds. Also, why shares slumped after BioMarin reported its gene therapy may virtually eliminate bleeding in hemophilia A patients.

Check out more of our content here:

1430 episodes available. A new episode about every 0 hours averaging 27 mins duration .